2020 Panels & Think Tanks
Developing Clinical Trial Outsourcing Strategies that Scale As Biotechs Do
Small- to mid-size clinical trial sponsors are increasingly important drivers of innovation in the pharma and biotech industry. Given their more limited R&D resources and in-house expertise, it is especially important for them to leverage outsourcing models that enable and accelerate clinical development quickly and cost-effectively. This panel will cover best practices small-to-mid-size organizations can employ to ensure flexibility, their ability to scale and increase the value of outsourcing partnerships over time.
Amir Malka, President & Co-Founder, Bioforum the Data Masters
Guy Goldberg, Chief Business Officer, RedHill Biopharma
Kanchan Relwani, VP and Head of Medical Affairs, Alkermes, 2020
Leading Global Teams
Leading a global team requires special skills and capabilities, which is more important than ever as life-sciences companies navigate a new world.
Adlai Goldberg, Global Digital, Social and Commercial Innovation Life Sciences Leader, EY, 2020
Guadalupe Hayes-Mota, Director, Global Supply Chain and Manufacturing, Ultragenyx Pharmaceuticals, 2020
Susanne Munksted, Chief Precision Officer, Diaceutics
Rebecca Vermeulen, VP Strategy Lead Patients and Society, Roche, 2020
Brand Stewards: Creating an Omnichannel Experience for HCPs and Patients
Creating a platform to support patients and HCPs is more important than ever for brand managers. With many reps still restricted from making office visits, brand managers need to create alternative journeys to promote the company as well as individual brands.
Dave Ormesher, Founder, closerlook, Red Jacket, 2013, 2011, 2010
Ryan Billings, Head, US Oncology Digital Marketing & Customer Experience, GSK, 2020
Mario Nacinovich, VP, Marketing, Eyevance Pharmaceuticals, 2011, 2005
Remote Clinical Trials: Advantages and Challenges
Remote clinical trials are moving beyond the pilot stages.
Bill Byrom, Ph.D., VP, Product Strategy and Innovation, Signant Health, 2017, 2008
Joe Dustin, Head of Clinical Innovation, Bristol Myers Squibb
Craig Lipset, Founder, Clinical Innovation Partners, Red Jacket, 2016, 2010
Collaboration Across the Industry
One of the silver linings of the global pandemic has been an increase in collaboration across all stakeholders. But what comes next? Can the momentum be maintained as operations begin to normalize? Our panel of experts will discuss why multistakeholder collaboration not only raises the bar but can lead to greater productivity, increased efficiency, and better outcomes.
Steve Matas, Senior VP, Strategic Resourcing, Advanced Clinical, 2020
Peter Anastasiou, Executive VP and Head of North America, Lundbeck, 2020
Craig Serra, Global Head, Innovation Data Operations, Novartis, 2020
Driving Commercial Relevance
The importance of behavior-based decision making in early-stage development. Our focus would be on a) key considerations/questions to identify real opportunity (ie opportunity with market traction) b) key activities/analyses needed c) models for success.
Anshal Purohit, President, Purohit Navigation
Shannon Dahl, Ph.D., Chief Scientific Officer, Cell Care Therapeutics, 2018
Mary Frances Harmon, Senior VP, Corporate and Patient Relations, PTC Therapeutics, 2020
Kinnari Patel, Pharm.D., Chief Operating Officer & Head of Development, Executive VP, Rocket Pharmaceuticals, 2018
Unprecedented Public Support for Pharma:
An Opportunity to Lead Like Never Before
The pharmaceutical industry’s reputation is changing for the better, driven by the industry’s innovative and heartfelt response to the pandemic. Companies have an opportunity to build on their communications strategies and step up to lead important new conversations, with the understanding that the public is actively listening in a new way.
Wendy Lund, CEO, GCI Health, 2020
Rob Jekielek, Managing Director, Harris Poll
Laura Randa, VP Market Access, HEOR and Public Policy, Mycovia Pharmaceuticals, 2013, 2018
Diversity in Clinical Trials
MHP and RPM to democratize access to trials and increase diversity access for clinical trials and care.
Tami Klerr, Executive VP and Chief Business Development & Marketing Officer, PRA Health Sciences, 2012
Kent Thoelke, Executive Vice President and Chief Scientific Officer, PRA Health Sciences, 2013
Elizabeth Garner, MD, Chief Medical Officer, ObsEva, 2019
Jessica Scott, MD, JD, Head of R&D Patient Engagement Office, Takeda Pharmaceutical Company, 2020
Aligning Equity, Diversity, and Inclusion (EDI)
with a Corporate Mission/Purpose
Study after study shows that companies that have a strategy dedicated to aligning equity, diversity, and inclusion have better business performance, are more innovative, and have better retention numbers. But making sure this strategy is tied with a corporate mission/purpose is still not as common as it should be in the life-science industry, thought leaders discuss how companies can make smart choices and make a difference to their employee base and the industry at large.
Eric Dube, Ph.D., President and CEO, Retrophin, 2020
Laurie Cooke, President and CEO, Healthcare Businesswomen's Association, 2009, 2017
Robin Shapiro, CEO, TBWA\WorldHealth, 2020
Will Science Ever Marry Technology?
The value to the life sciences of collaboration between the great scientific minds of pharma and the great engineering minds of the analytics industry, especially as related to the pandemic, and the potential benefits offered by a global clinical neural network that would accelerate COVID-19 therapies, as well as drugs for other diseases.
Suresh Kaata, Founder and CEO, Saama Technologies, 2018
Sagar Anisingaraju, Chief Strategy Officer, Saama Technologies, 2020
Elliot Barnathan, M.D., FACC, FAHA, Senior Director, Cardiovascular Clinical Development, Janssen Research & Development, 2019
Jay Kaminski, Advisor, Health2047 Inc.
Clive Meanwell, M.D., Ph.D., Founder, The Medicines Company, 2016
Managing a Remote Workforce:
Case Studies in Maintaining Business Continuity
Did COVID change how you managed those external relationships? And could you point to a case study on how you maintained those relationships with patient groups beyond zoom meetings? In essence, was business interrupted and how did you solve the challenge?
Deb Tatton, Senior VP, Global Clinical Operations, Parexel, 2020
Erin Horvath, President, Distribution Services, AmerisourceBergen Corp., 2020
Nandini Ramani, Chief Operating Officer, Outcome Health, 2020
Jeffrey W. Sherman, MD, FACP, Executive VP and Chief Medical Officer, Horizon Therapeutics, 2020
The Patient Voice
Including the patient voice is more important than ever when it comes to drug development, our experts explore how the industry can do better.
Barry Greene, President, Alnylam Pharmaceuticals, Red Jacket, 2019, 2018
Jack Barrette, CEO, WEGO Health, 2019, 2006, 2005
Barby Ingle, President, International Pain Foundation, 2020
Roslyn Schneider, M.D., Founder, RozMD Patient Affairs Consulting LLC, 2018
What's Next ...
Our Red Jacket honorees explore some of the biggest trends that will impact the industry as we embrace the extraordinary opportunities that lie ahead as we look to new ways of thinking, acting, and being.
Al Altomari, CEO, Agile Therapeutics
Jeffrey Berkowitz, CEO and Director, Real Endpoints
Sharon Callahan, CEO, CDM & Chief Client Officer, Omnicom
Dr. Donald Deieso, Executive Chairman & CEO, WCG
Dr. Nancy Dreyer, Chief Scientific Officer & Senior Vice President, Real World Solutions, IQVIA
Dr. Cameron Durrant, Chairman & CEO, Humanigen
Barry Greene, President, Alnylam Pharmaceuticals
Dr. Amir Kalali, Chief Curator and Chairman, CNS Summit
Michele Keefe, President, Commercial Solutions, Syneos Health
Craig Lipset, Founder, Clinical Innovation Partners
Andrea McGonigle, Managing Director, Health & Life Science Business Development, Microsoft
Dave Ormesher, CEO and Founder, closerlook Inc.
Ahnal Purohit, Ph.D., Founder and CEO, Purohit Navigation
Mike Rea, CEO and Co-Founder, IDEA PHARMA
Julie Ross, President, Advanced Clinical
Leerom Segal, Co-Founder and Chairman, Klick Health
Wendy White, Co-Founder, RareiTi